500674 Share Price Performance
₹4,158.60
-1240.90 (-22.98%)
33.7% undervalued intrinsic discount
₹6,271.00
Fair Value
Price ₹4,158.60
AnalystConsensusTarget ₹6,271.00
AnalystLowTarget ₹4,800.00
Fair Value₹6,271.00
Share Pricen/a
Sanofi India Limited Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
500674 Community Narratives
AN
Fair Value ₹6.27k 33.7% undervalued intrinsic discount
Diabetes Care Focus And Premium Insulin Mix Will Drive Long-Term Earnings Power
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value ₹4.8k 13.4% undervalued intrinsic discount
Diabetes Focus And AI Execution Will Face Headwinds Yet Ultimately Support A Healthier Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Diabetes Focus And AI Execution Will Face Headwinds Yet Ultimately Support A Healthier Outlook
Catalysts About Sanofi India Sanofi India focuses on prescription medicines, with a core emphasis on diabetes and insulin therapies in the Indian market. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹4.8k
13.4% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
1.37% p.a.
Profit Margin
24.1%
Future PE
32.71x
Price in 2029
₹6.88k
Diabetes Care Focus And Premium Insulin Mix Will Drive Long-Term Earnings Power
Catalysts About Sanofi India Sanofi India focuses on diabetes care, with a leading insulin portfolio and partnerships that extend its reach in cardiovascular and central nervous system therapies. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
₹6.27k
33.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
1.37% p.a.
Profit Margin
23.86%
Future PE
43.17x
Price in 2028
₹8.99k
Trending Discussion
Recently Updated Narratives
AN
Diabetes Focus And AI Execution Will Face Headwinds Yet Ultimately Support A Healthier Outlook
Fair Value: ₹4.8k 13.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Diabetes Care Focus And Premium Insulin Mix Will Drive Long-Term Earnings Power
Fair Value: ₹6.27k 33.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sanofi India Limited Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 154.71
- 50.64%
- 18.44%
- 2.7%
About 500674
- Founded
- 1956
- Employees
- 1225
- CEO
- WebsiteView website
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
